Amryt Pharma, a company focused on treatments for rare and orphan diseases, has appointed Jordi Casals as the biopharma’s head of Europe.
Taking responsibility for leading and developing Amryt’s European operations, Casals’ new role will see him initially focus on the sales growth of the company’s commercial asset Lojuxta – a treatment for adult patients with Homozygous Familial Hypercholesterolaemia.
Dr Joe Wiley, chief executive officer of Amryt, said: “I am pleased to welcome Jordi to our senior management team as the company’s head of Europe.
“His significant commercial experience of European markets will help us to drive and further develop Amryt’s growth across this key region.”
Casal has over 20 years’ experience in the pharmaceutical and biotech industry and most recently worked for Aegerion Pharmaceuticals as a consultant, managing its commercial operations in the Iberia region.
Prior to this, he worked for eight years at Alexion Pharmaceuticals, latterly as vice president commercial operations, Western Europe.